LANTERN PHARMA DL-,0001

Lantern Pharma reported a loss of $0.57 per share for Q2/2026, significantly worse than the $0.38 expected, driven mainly by about $3.6 million in non-cash charges from warrants issued in May. Operationally the company improved: operating expenses fell 25% and R&D costs dropped 42%, while the operating loss narrowed to $3.5 million. Lantern has $7.4 million in cash, is advancing clinical programs (including LP-300, LP-184) and the spin-off of Open-Medicine AI, but cites additional financing as a priority; the stock fell in premarket trading. » Plus sur de.investing.com

Lantern Pharma has commercially launched the withZeta.ai AI platform as a subscription service for drug discovery in rare cancers and biomedical research. The platform is based on RADR technology, uses a multi‑agent architecture and a 24‑billion‑parameter AI model, covers 438 cancer types and offers three research modes as well as three subscription tiers. Lantern is presenting withZeta.ai at investor meetings at the Nasdaq MarketSite and at the annual meeting of the American Association for Cancer Research; the stock rose 26% after the announcement. The clinical‑stage company has a market capitalization of $24.88 million, remains unprofitable and expects a loss of $1.60 per share for 2026. » Plus sur de.investing.com

Lantern Pharma reported an adjusted net loss of $0.36 per share for Q4 2025, beating the $0.54 expectation, supported by significant cost discipline. Despite clinical progress and multiple FDA special designations, cash on hand has fallen to $10.12 million, obliging management to secure additional financing or partnerships by mid-2026. Key achievements include completing recruitment for LP-300 in Japan, promising Phase‑1a data for LP-184, a recommended Phase‑2 dose, and further development of the AI platform RADR and new tools such as Zeta and PredictBBB. » Plus sur de.investing.com